MedTrace Logo

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 453

Last updated 2020-10-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.

Conditions

Interventions

DRUG

Ethosuximide

Ethosuximide is a common treatment for childhood absence epilepsy.

DRUG

Lamotrigine

Lamotrigine is a common treatment for childhood absence epilepsy.

DRUG

Valproic acid

Valproic acid is a common treatment for childhood absence epilepsy.

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Tracy A. Glauser, MD · Children's Hospital Medical Center, Cincinnati

  • Peter Adamson, MD · Children's Hospital of Philadelphia

  • Avital Cnaan, PhD · Children's National Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Months
Max Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2013-01-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088452 on ClinicalTrials.gov